References
Aboushousha, R., Elko, E., Chia, S. B., Manuel, A. M., van de Wetering, C., van der Velden, J., MacPherson, M., Erickson, C., Reisz, J. A., D’Alessandro, A., Wouters, E. F. M., Reynaert, N. L., Lam, Y.-W., Anathy, V., van der Vliet, A., Seward, D. J., & Janssen-Heininger, Y. M. W. (2021). Glutathionylation chemistry promotes interleukin-1 beta-mediated glycolytic reprogramming and pro-inflammatory signaling in lung epithelial cells. FASEB Journal : Official Publication of the Federation of American Societies For Experimental Biology ,35 (5), e21525.https://doi.org/10.1096/fj.202002687RR
Arthur, J. S. C., & Ley, S. C. (2013). Mitogen-activated protein kinases in innate immunity. Nature Reviews. Immunology ,13 (9), 679-692.https://doi.org/10.1038/nri3495
Badouel, C., Garg, A., & McNeill, H. (2009). Herding Hippos: regulating growth in flies and man. Current Opinion In Cell Biology ,21 (6), 837-843.https://doi.org/10.1016/j.ceb.2009.09.010
Baker, T. A., Bach, H. H., Gamelli, R. L., Love, R. B., & Majetschak, M. (2014). Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases. Physiological Research ,63 (3), 311-319.https://pubmed.ncbi.nlm.nih.gov/24564596
Bizargity, P., Liu, K., Wang, L., Hancock, W. W., & Visner, G. A. (2012). Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection. Transplantation , 94 (2), 114-122.https://doi.org/10.1097/TP.0b013e3182584879
Cao, Z.-J., Liu, Y., Zhang, Z., Yang, P.-R., Li, Z.-G., Song, M.-Y., Qi, X.-M., Han, Z.-F., Pang, J.-L., Li, B.-C., Zhang, X.-R., Dai, H.-P., Wang, J., & Wang, C. (2022). Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A. Acta Pharmacologica Sinica , 43 (4), 908-918.https://doi.org/10.1038/s41401-021-00706-4
Cao, Z., Song, M., Liu, Y., Pang, J., Li, Z., Qi, X., Shu, T., Li, B., Wei, D., Chen, J., Li, B., Wang, J., & Wang, C. (2020). A novel pathophysiological classification of silicosis models provides some new insights into the progression of the disease. Ecotoxicol Environ Saf , 202 , 110834.https://doi.org/10.1016/j.ecoenv.2020.110834
Cao, Z., Song, M., Liu, Y., Pang, J., Li, Z., Qi, X., Shu, T., Li, B., Wei, D., Chen, J., Li, B., Wang, J., & Wang, C. (2020). A novel pathophysiological classification of silicosis models provides some new insights into the progression of the disease. Ecotoxicology and Environmental Safety , 202 , 110834.https://doi.org/10.1016/j.ecoenv.2020.110834
Collins, B. F., & Raghu, G. (2019). Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. European Respiratory Review : an Official Journal of the European Respiratory Society , 28 (153).https://doi.org/10.1183/16000617.0022-2019
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014). Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences , 58 , 13-19.https://doi.org/10.1016/j.ejps.2014.02.014
Cunningham, P. S., Meijer, P., Nazgiewicz, A., Anderson, S. G., Borthwick, L. A., Bagnall, J., Kitchen, G. B., Lodyga, M., Begley, N., Venkateswaran, R. V., Shah, R., Mercer, P. F., Durrington, H. J., Henderson, N. C., Piper-Hanley, K., Fisher, A. J., Chambers, R. C., Bechtold, D. A., Gibbs, J. E., . . . Blaikley, J. F. (2020). The circadian clock protein REVERBα inhibits pulmonary fibrosis development.Proceedings of the National Academy of Sciences of the United States of America , 117 (2), 1139-1147.https://doi.org/10.1073/pnas.1912109117
Guo, J., Yang, Z., Jia, Q., Bo, C., Shao, H., & Zhang, Z. (2019). Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model. Toxicology Letters ,300 , 59-66.https://doi.org/10.1016/j.toxlet.2018.10.019
Gurujeyalakshmi, G., Hollinger, M. A., & Giri, S. N. (1999). Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. The American Journal of Physiology , 276 (2), L311-L318.https://doi.org/10.1152/ajplung.1999.276.2.L311
Hirano, A., Kanehiro, A., Ono, K., Ito, W., Yoshida, A., Okada, C., Nakashima, H., Tanimoto, Y., Kataoka, M., Gelfand, E. W., & Tanimoto, M. (2006). Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. American Journal of Respiratory Cell and Molecular Biology , 35 (3), 366-377.https://pubmed.ncbi.nlm.nih.gov/16675785
King, E. J. (1952). Silicosis. Lect Sci Basis Med , 2 , 108-138.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W. (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.The New England Journal of Medicine , 370 (22), 2083-2092.https://doi.org/10.1056/NEJMoa1402582
King, T. E., Pardo, A., & Selman, M. (2011). Idiopathic pulmonary fibrosis. Lancet (London, England) , 378 (9807), 1949-1961.https://doi.org/10.1016/S0140-6736(11)60052-4
Leung, C. C., Yu, I. T. S., & Chen, W. (2012). Silicosis. Lancet (London, England) , 379 (9830), 2008-2018.https://doi.org/10.1016/S0140-6736(12)60235-9
Ma, Z., Zhao, C., Chen, Q., Yu, C., Zhang, H., Zhang, Z., Huang, W., & Shen, Z. (2018). Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Pulmonary Pharmacology & Therapeutics ,53 , 100-106.https://doi.org/10.1016/j.pupt.2018.10.006
Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinas, E., Luburich-Hernaiz, P., Dorca, J., & Montes-Worboys, A. (2018). Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulmonary Medicine , 18 (1), 63.https://doi.org/10.1186/s12890-018-0626-4
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., Lederer, D. J., Pereira, C. A., Swigris, J. J., Valeyre, D., & Noble, P. W. (2017). Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. The Lancet. Respiratory Medicine ,5 (1), 33-41.https://doi.org/10.1016/S2213-2600(16)30326-5
Nathan, S. D., Costabel, U., Glaspole, I., Glassberg, M. K., Lancaster, L. H., Lederer, D. J., Pereira, C. A., Trzaskoma, B., Morgenthien, E. A., Limb, S. L., & Wells, A. U. (2019). Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest , 155 (4), 712-719.https://doi.org/10.1016/j.chest.2018.11.008
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., Lederer, D. J., Leff, J. A., Nathan, S. D., Pereira, C. A., Swigris, J. J., Valeyre, D., & King, T. E. (2016). Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. The European Respiratory Journal , 47 (1), 243-253.https://doi.org/10.1183/13993003.00026-2015
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., Valeyre, D., & du Bois, R. M. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet (London, England) , 377 (9779), 1760-1769.https://doi.org/10.1016/S0140-6736(11)60405-4
Pang, J., Qi, X., Luo, Y., Li, X., Shu, T., Li, B., Song, M., Liu, Y., Wei, D., Chen, J., Wang, J., & Wang, C. (2021). Multi-omics study of silicosis reveals the potential therapeutic targets PGD(2) and TXA(2).Theranostics , 11 (5), 2381-2394.https://doi.org/10.7150/thno.47627
Paterniti, M. O., Bi, Y., Rekić, D., Wang, Y., Karimi-Shah, B. A., & Chowdhury, B. A. (2017). Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society , 14 (9), 1395-1402.https://doi.org/10.1513/AnnalsATS.201606-458OC
Pekovic-Vaughan, V., Gibbs, J., Yoshitane, H., Yang, N., Pathiranage, D., Guo, B., Sagami, A., Taguchi, K., Bechtold, D., Loudon, A., Yamamoto, M., Chan, J., van der Horst, G. T. J., Fukada, Y., & Meng, Q.-J. (2014). The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes & Development , 28 (6), 548-560.https://doi.org/10.1101/gad.237081.113
Qian, F., Deng, J., Wang, G., Ye, R. D., & Christman, J. W. (2016). Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases. Current Protein & Peptide Science , 17 (4), 332-342.https://pubmed.ncbi.nlm.nih.gov/26119506
Qin, W., Liu, B., Yi, M., Li, L., Tang, Y., Wu, B., & Yuan, X. (2018). Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. Radiation Research , 190 (4), 396-403.https://doi.org/10.1667/RR15017.1
Qiu, M., Qin, L., Dong, Y., Ma, J., Yang, Z., & Gao, Z. (2022). The study of metabolism and metabolomics in a mouse model of silica pulmonary fibrosis based on UHPLC-QE-MS. Artificial Cells, Nanomedicine, and Biotechnology , 50 (1), 322-330.https://doi.org/10.1080/21691401.2022.2124517
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M. (2011). Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. The New England Journal of Medicine , 365 (12), 1079-1087.https://doi.org/10.1056/NEJMoa1103690
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016). Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respiratory Medicine , 113 , 74-79.https://doi.org/10.1016/j.rmed.2016.02.001
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., . . . Collard, H. R. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England Journal of Medicine , 370 (22), 2071-2082.https://doi.org/10.1056/NEJMoa1402584
Spond, J., Case, N., Chapman, R. W., Crawley, Y., Egan, R. W., Fine, J., Hey, J. A., Kreutner, W., Kung, T., Wang, P., & Minnicozzi, M. (2003). Inhibition of experimental acute pulmonary inflammation by pirfenidone.Pulmonary Pharmacology & Therapeutics , 16 (4), 207-214.https://pubmed.ncbi.nlm.nih.gov/12850123
Szapiel SV, E. N., Fulmer JD, Hunninghake GW, Crystal RG. . (1979). Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis , 120(4):893-899.https://doi.org/10.1164/arrd.1979.120.4.893
Tang, Q., Xing, C., Li, M., Jia, Q., Bo, C., & Zhang, Z. (2022). Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways. Ecotoxicology and Environmental Safety ,244 , 114066.https://doi.org/10.1016/j.ecoenv.2022.114066
Toda, M., Mizuguchi, S., Minamiyama, Y., Yamamoto-Oka, H., Aota, T., Kubo, S., Nishiyama, N., Shibata, T., & Takemura, S. (2018). Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts. Journal of Clinical Biochemistry and Nutrition , 63 (1), 58-65.https://doi.org/10.3164/jcbn.17-111
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., & Wuyts, W. A. (2018). Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine , 197 (3), 356-363.https://doi.org/10.1164/rccm.201706-1301OC
Visner, G. A., Liu, F., Bizargity, P., Liu, H., Liu, K., Yang, J., Wang, L., & Hancock, W. W. (2009). Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation , 88 (3), 330-338.https://doi.org/10.1097/TP.0b013e3181ae3392
Wang, Q., Sundar, I. K., Lucas, J. H., Park, J.-G., Nogales, A., Martinez-Sobrido, L., & Rahman, I. (2023). Circadian clock molecule REV-ERBα regulates lung fibrotic progression through collagen stabilization. Nature Communications , 14 (1), 1295.https://doi.org/10.1038/s41467-023-36896-0
Wang, W., Liu, H., Dai, X., Fang, S., Wang, X., Zhang, Y., Yao, H., Zhang, X., & Chao, J. (2015). p53/PUMA expression in human pulmonary fibroblasts mediates cell activation and migration in silicosis.Scientific Reports , 5 , 16900.https://doi.org/10.1038/srep16900
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014). Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.The Journal of Pharmacology and Experimental Therapeutics ,349 (2), 209-220.https://doi.org/10.1124/jpet.113.208223
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. The European Respiratory Journal , 45 (5), 1434-1445.https://doi.org/10.1183/09031936.00174914
Yu, G., Wang, L. G., Han, Y., & He, Q. Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters.OMICS , 16 (5), 284-287.https://doi.org/10.1089/omi.2011.0118